Shrinkage estimation for dose-response modeling in phase II trials with multiple schedules

References

• Alexander, H., Patton, T., Jabbar-Lopez, Z., Manca, A., and Flohr, C. (2019). Novel systemic therapies in atopic dermatitis: what do we need to fulfill the promise of a treatment revolution? F1000Research, 8(132).
   Google Scholar
• Ballantyne, C., Neutel, J., Cropp, A., Duggan, W., Wang, E., Plowchalk, D., Sweeney, K., Kaila, N., Vincent, J., and Bays, H. (2014). Efficacy and safety of bococizumab (rn316/pf-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: Results from a randomized, placebo-controlled, dose-ranging study. Journal of the American College of Cardiology, 63(12 Supplement):A1374.
   Google Scholar
• Betancourt, M. and Girolami, M. (2015). Current trends in Bayesian methodology with applications, chapter 4, pages 79–103. CRC Press, Boca Raton.
   Google Scholar
• Bornkamp, B. (2012). Functional uniform priors for nonlinear modeling. Biometrics, 68(3):893–901.
   Google Scholar
• Bornkamp, B. (2014). Practical considerations for using functional uniform prior distributions for dose-response estimation in clinical trials. Biometrical Journal, 56(6):947–962.
   Google Scholar
• Bornkamp, B., Pinheiro, J., and Bretz, F. (2018). Dosefinding: Planning and analyzing dose finding experiments. https://CRAN.R-project.org/package=DoseFinding. R package version 0.9-16.
   Google Scholar
• Bretz, F., Pinheiro, J., and Branson, M. (2005). Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics, 61(3):738–748.
   Google Scholar
• Carpenter, B., Gelman, A., Hoffman, M., Lee, D., Goodrich, B., Betancourt, M., Brubaker, M., Guo, J., Li, P., and Riddell, A. (2017). Stan: A probabilistic programming language. Journal of Statistical Software, 76(1):1–32.
   Google Scholar
• Efron, B. and Morris, C. (1975). Data analysis using Stein’s estimator and its generalizations. Journal of the American Statistical Association, 70(350):311–319.
   Google Scholar
• Eichenfield, L. and Stein Gold, L. (2017). Systemic therapy of atopic dermatitis: Welcome to the revolution. Seminars in Cutaneous Medicine and Surgery, 36(4S):S103–S105.
   Google Scholar
• Feller, C., Schorning, K., Dette, H., Bermann, G., and Bornkamp, B. (2017). Optimal designs for dose response curves with common parameters. Annals of Statistics, 45(5):2102–2132.
   Google Scholar
• Freidlin, B. and Korn, E. (2013). Borrowing information across subgroups in phase II trials: Is it useful? Clinical Cancer Research, 19(6):1326–1334.
   Google Scholar
• Friede, T., Röver, C., Wandel, S., and Neuenschwander, B. (2017). Meta-analysis of few small studies in orphan diseases. Research Synthesis Methods, 8(1):79–91.
   Google Scholar
• Gelman, A. (2006). Prior distributions for variance parameters in hierarchical models (comment on article by browne and draper). Bayesian Analysis, 1(3):515–534.
   Google Scholar
• Giugliano, R., Desai, N., Kohli, P., Rogers, W., Somaratne, R., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E., McDonald, S., Abrahamsen, T., Wasserman, S., Scott, R., and Sabatine, M. (2012). Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. The Lancet, 380(9858):2007–2017.
   Google Scholar
• Greenland, S. (2000). Principles of multilevel modelling. International Journal of Epidemiology, 29(1):158–167.
   Google Scholar
• Günhan, B. K., Röver, C., and Friede, T. (2020a). Random-effects meta-analysis of few studies involving rare events. Research Synthesis Methods, 11(1):74–90.
   Google Scholar
• Günhan, B. K., Weber, S., and Friede, T. (2020b). A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules. Statistics in Medicine, pages 1–15.
   Google Scholar
• Jones, H., Ohlssen, D., Neuenschwander, B., Racine, A., and Branson, M. (2011). Bayesian models for subgroup analysis in clinical trials. Clinical Trials, 8(2):129–143.
   Google Scholar
• Mayo Clinic (2018). Atopic Dermatitis. https://www.mayoclinic.org/diseases-conditions/atopic-dermatitis-eczema/symptoms-causes/syc-20353273. Updated March, 2018. Accessed January, 2020.
   Google Scholar
• Mayo Clinic (2019). High cholesterol. https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/symptoms-causes/syc-20350800. Updated July, 2019. Accessed August, 2020.
   Google Scholar
• Möllenhoff, K., Bretz, F., and Dette, H. (2020). Equivalence of regression curves sharing common parameters. Biometrics, 76(2):518–529.
   Google Scholar
• MorphoSys AG (2019). MOR106 clinical development in atopic dermatitis stopped. https://www.morphosys.com/media-investors/media-center/morphosys-ag-mor106-clinical-development-in-atopic-dermatitis-stopped. Updated October, 2019. Accessed January, 2020.
   Google Scholar
• Neuenschwander, B., Wandel, S., Roychoudhury, S., and Bailey, S. (2016). Robust exchangeability designs for early phase clinical trials with multiple strata. Pharmaceutical Statistics, 15(2):123–134.
   Google Scholar
• Pfizer (2017). Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin. https://clinicaltrials.gov/ct2/show/results/NCT01592240?cond=NCT01592240&draw=2&rank=1&view=results. Identification No. NCT01592240. Updated December, 2017. Accessed August, 2020.
   Google Scholar
• Röver, C., Bender, R., Dias, S., Schmid, C. H., Schmidli, H., Sturtz, S., Weber, S., and Friede, T. (2020). On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis. https://arxiv.org/abs/2007.08352. Updated Jul, 2020. Accessed Oct, 2020.
   Google Scholar
• Röver, C. and Friede, T. (2020). Dynamically borrowing strength from another study through shrinkage estimation. Statistical Methods in Medical Research, 29(1):293–308.
   Google Scholar
• Ruberg, S. (1995). Dose response studies I. some design considerations. Journal of Biopharmaceutical Statistics, 5(1):1–14.
   Google Scholar
• Schorning, K., Bornkamp, B., Bretz, F., and Dette, H. (2016). Model selection versus model averaging in dose finding studies. Statistics in Medicine, 35(22):4021–4040.
   Google Scholar
• Spiegelhalter, D., Abrams, K., and Myles, J. P. d. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. West Sussex: CRC Press.
   Google Scholar
• Stan Development Team (2018). Stan modeling language users guide and reference manual, version 2.18.0. http://mc-stan.org/.
   Google Scholar
• Thaçi, D., Simpson, E., Beck, L., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J., Sofen, H., et al. (2016). Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. The Lancet, 387(10013):40–52.
   Google Scholar
• Thomas, N., Sweeney, K., and Somayaji, V. (2014). Meta-analysis of clinical dose-response in a large drug development portfolio. Statistics in Biopharmaceutical Research, 6(4):302–317.
   Google Scholar
• Thomas, N. and Wu, J. (2020). clindr: Simulation and analysis tools for clinical dose response modeling. https://CRAN.R-project.org/package=clinDR. R package version 2.3.
   Google Scholar
• Ursino, M., Zohar, S., Lentz, F., Alberti, C., Friede, T., Stallard, N., and Comets, E. (2017). Dose-finding methods for phase i clinical trials using pharmacokinetics in small populations. Biometrical Journal, 59(4):804–825.
   Google Scholar
• Varadhan, R. (2015). alabama: Constrained nonlinear optimization. https://CRAN.R-project.org/package=alabama. R package version 2015.3-1.
   Google Scholar
• Vehtari, A., Gelman, A., and Gabry, J. (2017). Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Statistics and Computing, 27(5):1413–1432.
   Google Scholar
• Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J. G., Kinnersley, N., Lindborg, S., Micallef, S., Roychoudhury, S., and Thompson, L. (2014). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics, 13(1):41–54.
   Google Scholar